Atlas Trials

A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

Clinical trial NCT04212013 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04212013
Sponsor
Memorial Sloan Kettering Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Marginal Zone Lymphoma
Start date
2019-12-23
Primary completion
2027-03-18
Enrollment
23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.